A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

Campaign aims to improve lung cancer survival through early detection, education and widespread access to biomarker testing. CHICAGO, Aug. 20, 2025 /PRNewswire/ -- For people with lung cancer, ...

Lung adenocarcinoma (LUAD) is the most common form of lung cancer, accounting for nearly half of cases. Many patients are ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing. Dr. Joshua K. Sabari, a thoracic medical ...

Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based Cancer ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

The results of non-biomarker blood tests (tests that aren't specifically looking for lung cancer) are usually nonspecific (meaning that the finding could be due to many different medical conditions) ...

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality despite recent advances in immunotherapy, particularly with immune checkpoint ...

The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer. Physicians can use the test to ...

In cancer patients, the health of the thymus—a key part of the body's immune system—is associated with the outcomes these ...